Lodelcizumab, a recently identified monoclonal antibody, represents a promising alternative in the battle against chronic migraines. Unlike many available therapies that focus pain itself, lodelcizumab uniquely blocks CGRP, a key protein linked in migraine onset. This unique mechanism of action m

Emibetuzumab, initially known as LY2875358, represents a novel treatment method in oncology, specifically targeting the MET tyrosine protein. This engineered immunoglobulin operates by primarily attaching to the HGFR molecule, restricting its engagement and subsequent subsequent signaling. Precli

Datopotamab Deruxtecan, often abbreviated as DATO, represents an important advancement in targeted cancer care. This new antibody-drug conjugate joins a monoclonal immunoglobulin specifically directed at HER2 positive expressing cells with the potent cytotoxic payload, deruxtecan. The mechanism o